105728-06-1

Basic information

• Product Name: (3-FORMYL-4-NITROPHENOXY)ACETIC ACID
• Synonyms: (3-FORMYL-4-NITROPHENOXY)ACETIC ACID;Acetic acid,2-(3-formyl-4-nitrophenoxy)-
• CAS NO: 105728-06-1
• Molecular Formula: C₉H₇NO₆
• Molecular Weight: 225.15
• Mol File: 105728-06-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3-FORMYL-4-NITROPHENOXY)ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (3-FORMYL-4-NITROPHENOXY)ACETIC ACID(105728-06-1)
• EPA Substance Registry System: (3-FORMYL-4-NITROPHENOXY)ACETIC ACID(105728-06-1)

Safety Data

• Hazardous Substances Data: 105728-06-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
(3-FORMYL-4-NITROPHENOXY)ACETIC ACID is used as a key intermediate in the synthesis of various pharmaceuticals for its potential biological activities, contributing to the development of new drugs with therapeutic benefits.
Used in Agrochemical Production:
In the agrochemical industry, (3-FORMYL-4-NITROPHENOXY)ACETIC ACID is employed as an intermediate in the production of compounds that have applications in crop protection and pest management, enhancing agricultural productivity.
Used in Organic Compounds and Dyes Synthesis:
(3-FORMYL-4-NITROPHENOXY)ACETIC ACID is utilized as an intermediate in the synthesis of other organic compounds and dyes, contributing to the coloration and functional properties of various products.
Used in Medicinal Chemistry Research:
(3-FORMYL-4-NITROPHENOXY)ACETIC ACID is studied for its potential anticancer and antimicrobial properties, making it a compound of interest in the field of medicinal chemistry. Its exploration in these areas could lead to the discovery of new therapeutic agents and treatments.

Upstream product

• 105728-02-7 (3-Formyl-4-nitro-phenoxy)-acetic acid ethyl ester 
• 42454-06-8 2-nitro-5-hydroxybenzaldehyde 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 105695-40-7 N-cyclohexyl-N-methyl-2-(2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-7-yl)oxyacetamide 
• 105728-10-7 N-Cyclohexyl-2-(3-formyl-4-nitro-phenoxy)-N-methyl-acetamide 

Relevant articles and documents

Hapten synthesis, monoclonal antibody production and immunoassay development for direct detection of 4-hydroxybenzehydrazide in chicken, the metabolite of nifuroxazide

Derivatization is usually employed in immunoassay for detection of metabolites of nitrofurans and avoiding derivatization could be preferable to achieve an efficient screening. In the study, we designed four haptens of 4-hydroxybenhydrazide (HBH), the nifuroxazide metabolite. The effect of hapten structures on antibody affinity were evaluated and one monoclonal antibody was produced by using the Hapten C with a linear alkalane spacer arm. After optimization, an enzyme linked-immunosorbent assay (ELISA) was established with an 50% inhibition concentration of 0.25 ng mL?1 for HBH, which could ensure the direct detection of HBH without derivatization. The limit of detection of the ELISA for HBH was 0.12 μg kg?1 with the recoveries of 90.1–96.2% and coefficient of variation (CV) values lower than 9.1%. In conclusion, we produced several high affinity antibodies to HBH with new designed hapten and developed an icELISA for the direct detection of HBH without derivatization in chicken.

Nifursol hapten, artificial antigen, and preparation method and application thereof

The invention relates to the field of biochemical engineering, and specifically relates to a nifursol hapten, an artificial antigen, and a preparation method and application thereof. The structure of the nifursol hapten is shown as a formula (I), the artificial antigen is obtained after the nifursol hapten is coupled with carrier protein, the artificial antigen is used as an immunogen to prepare a corresponding hybridoma cell 3H10, and a monoclonal antibody secreted by the hybridoma cell 3H10 can be used for detecting nifursol. A monoclonal antibody prepared by immunizing a mouse with an artificial antigen prepared from the nifursol hapten provided by the invention has relatively high sensitivity in detection of nifursol and derivatives thereof, and a new material basis is provided for establishing a rapid, simple, cheap, sensitive and specific nifursol detection method.

Nifuroxazide hapten, nifuroxazide artificial antigen, preparation method of artificial antigen and application of nifuroxazide hapten and artificial antigen

The invention relates to a nifuroxazide hapten, a nifuroxazide artificial antigen, a preparation method of the artificial antigen and application of the nifuroxazide hapten and nifuroxazide artificialantigen. The structure of the nifuroxazide hapten is shown in a formula (I) or formula (II), and the nifuroxazide artificial antigen is prepared through coupling of the hapten in the formula (I) or formula (II) and carrier protein. When the nifuroxazide artificial antigen is applied to immunity of animals, specific antibodies with high cost performance and high sensitivity can be obtained. A newway is provided for establishment of a fast, simple, inexpensive, sensitive and specific detection method of nifuroxazide through the nifuroxazide hapten and the antibodies which are prepared from thenifuroxazide hapten.

Nifuraldezone hapten and artificial antigen as well as preparation method and application thereof

The invention relates to nifuraldezone hapten and artificial antigen as well as a preparation method and application thereof. The nifuraldezone hapten has a structural formula (I) or (II) shown in thedescription. The nifuraldezone artificial antigen is prepared by coupling the hapten of the formula (I) or (II) with a carrier protein. When the nifuraldezone artificial antigen is adopted to immunize animals, specific antibodies with high valences and high sensitivity can be obtained. By adopting the nifuraldezone hapten and antibodies prepared from same, novel means for establishing rapid, simple, cheap, sensitive and specific nifuraldezone detection methods can be provided.

Inhibitors of Cyclic AMP Phosphodiesterase. 2. Structural Variations of N-Cyclohexyl-N-methyl-4-quinazolin-7-yl)oxy>butyramide (RS-82856)

A series of analogues of the cyclic AMP phosphodiesterase (PDE) inhibitor N-cyclohexyl-N-methyl-4-quinazolin-7-yl)oxy>butyramide (RS-82856, 1) was prepared by systematic variation of the side-chain substituent, length, position, connecting atom, and the parent heterocycle itself.The compounds were evaluated as inhibitors of cyclic AMP phosphodiesterase from both human platelets and rat or dog heart tissue and as inhibitors of ADP-induced platelet aggregation.Structure-activity correlations for the analogue series revealed significant limitations on the steric bulk of substituents on the 1,2,3,5-tetrahydroimidazoquinaazolin-2-one heterocycle and the position and length of the side-chain.As inhibitors of cyclic AMP phosphodiesterase (PDE), potency steadily increased with increasingly lipophilic side chains.In platelet aggregation inhibition studies, however, a maximum in activity was reached with 1, while more lipophilic compounds were significantly less active.Major changes in the heterocycle itself, represented by isomeric and other carbonyl variations, also decreased activity.The molecular features defined by this series of analogues of 1 correlate to a high degree with current understanding of thr chemical and topographical requirements of the active site of the FIII (type IV) form of cyclic AMP PDE.Selective inhibition of this enzyme has been proposed as the principal component of the positive inotropic action of a number of cardiotonic agents.

(2-oxo-3-methylene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolinyl)oxyalkylamides useful as cyclic AMP phosphodiesterase inhibitors

This invention relates to compounds of the formula (I) and the pharmaceutically acceptable acid addition salts thereof wherein the various substituents are defined herein. These compounds are cyclic AMP phosphodiesterase inhibitors useful as antithrombotic and inotropic agents in mammals